Seeking Alpha

Ariad says AP26113 continues to show promise in advanced NSCLC

At the European Cancer Congress, Ariad Pharmaceuticals (ARIA) gives an update on the Phase 1/2 trial of AP26113.

According to the company, the tyrosine kinase inhibitor demonstrated "robust anti-tumor activity" in patients with TKI-naïve and crizotinib-resistant ALK+  non-small cell lung cancer.

Additionally, it appears the drug is active in patients with brain metastases. (PR)

From other sites
Comments (1)
  • Benyas
    , contributor
    Comments (68) | Send Message
    The results that they report are very encouraging. The fact that "113" crosses the blood brain barrier and shrinks metastatic brain lesions is downright exciting. If you want some insight as to what the company really thinks about the future of what they have I suggest you look at the report they issued to the SEC on 9/19/2013 about the amendment to their lease agreement. Laugh if you like, but I think this action is related to "113". Benyas.
    29 Sep 2013, 09:41 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs